suramin + docetaxel + carboplatin

A **combination drug comprising suramin, docetaxel, and carboplatin**; suramin is a polysulfonated naphthylurea that, at low (non-cytotoxic) concentrations, acts as a chemosensitizer by interfering with several growth factors and their receptors (such as fibroblast growth factor), potentially enhancing the cytotoxicity of chemotherapeutic agents. Docetaxel is a taxane derivative that stabilizes microtubules, blocking cell division and inducing apoptosis, while carboplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and leads to apoptosis. The combination has been studied in platinum-refractory or relapsed non-small cell lung cancer, where suramin is hypothesized to potentiate the effects of standard cytotoxic chemotherapy, including taxanes and platinum agents.